Contact us to learn more about

our Premium Content: News alerts, weekly reports and conference planners

DRUG:

TmEGFR/IL13Rα2 01 CAR-T

Contact us to learn more about our Premium Content:

News alerts, weekly reports and conference planners

Company:

Gilead, University of Pennsylvania

Drug class:

EGFR-targeted CAR-T immunotherapy, IL-13-targeted CAR-T immunotherapy

Related drugs:

EGFR806-specific CAR T-cell therapy (1)

CXCR5 Modified EGFR Targeted CAR-T Cells (0)

EGFR IL12 CART cells (0)

GPC3/Mesothelin/Claudin18.2/GUCY2C/B7-H3/PSCA/PSMA/MUC1/TGFβ/HER2/Lewis-Y/AXL/EGFR-CAR-T cells (0)

Undisclosed EGFR/B7H3 CAR-T (0)

EGFR806-specific CAR T-cell therapy (1)

CXCR5 Modified EGFR Targeted CAR-T Cells (0)

EGFR IL12 CART cells (0)

GPC3/Mesothelin/Claudin18.2/GUCY2C/B7-H3/PSCA/PSMA/MUC1/TGFβ/HER2/Lewis-Y/AXL/EGFR-CAR-T cells (0)

Undisclosed EGFR/B7H3 CAR-T (0)